Cardiometabolic Risk Assessment in Transgender Individuals—Differential Effect of Sex Hormones and Sex Chromosomes - Takeaways - MDSpire

Cardiometabolic Risk Assessment in Transgender Individuals—Differential Effect of Sex Hormones and Sex Chromosomes

  • By

  • Yu Lei

  • Anna Wiik

  • Margery A Connelly

  • Linnea Lindberg

  • Daniel P Andersson

  • Stefan Arver

  • Thomas Gustafsson

  • Uwe J F Tietge

  • October 23, 2024

  • 0 min

Share

  • 1

    The study evaluated cardiometabolic risk in 17 transgender men and 17 transgender women over 11 months of gender-affirming hormone treatment.

  • 2

    Transgender men exhibited increased cardiometabolic risk, including a proatherogenic lipoprotein profile and elevated plasma glucose levels.

  • 3

    Transgender women showed beneficial changes in cardiometabolic markers early in hormone therapy, with decreased cholesterol efflux capacity.

  • 4

    Sex chromosomes had fewer intrinsic effects on cardiometabolic risk, with XY individuals and transgender men displaying higher diabetes risk.

  • 5

    The findings highlight the need for further research on cardiometabolic risk in transgender populations to improve risk prediction and management.

Original Source(s)

Cardiometabolic Risk Assessment in Transgender Individuals—Differential Effect of Sex Hormones and Sex Chromosomes

  • by Yu Lei, Anna Wiik, Margery A Connelly, Linnea Lindberg, Daniel P Andersson, Stefan Arver, Thomas Gustafsson, Uwe J F Tietge

  • October 23, 2024

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Keeping an Eye on Diabetes

Progress, pitfalls and the future of the UK’s Diabetic Eye Screening Program

Metformin’s Potential Role in Posterior Capsule Opacification

Common diabetes therapy reaches intraocular lens tissue and may help limit PCO, says newly published data

  • March 30, 2026

  • 3 min